Latest Illumina rejection stings Roche

The dance continues. Illumina ($ILMN) is standing firm against Roche's ($RHHBY) ongoing attempts to take it over. The Illumina board has urged the rejection of the Swiss giant's increased offer of $51 per share. Roche expressed disappointment in the recalcitrance of the board. "Roche's increased offer is highly attractive. By not engaging with Roche, Illumina reinforces the notion that its Board and management are determined to preserve their positions rather than maximize shareholder value," said Roche CEO Severin Schwan in a statement. Roche release

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.